BeiGene Canada is led by a highly experienced and dedicated Canadian team with a shared passion for extending the boundaries of ‘possible’. In close collaboration with global colleagues, we deliver on our promise of bringing best-in-class, affordable and accessible treatments to the Canadian oncology community.
Peter Brenders, MBA, HBSc
As BeiGene Canada’s General Manager, Peter Brenders is responsible for building and leading Canadian affiliate operations, strategic planning, cross-functional teams, and driving domestic growth opportunities making new and innovative oncology therapies accessible and affordable to Canadians in need.
A seasoned and award-winning leader, Peter is passionate about patient-centered care with specific expertise in the areas of hematology, oncology, neurology, and rare diseases. For over two decades he has driven strategic partnerships and growth in the digital and life sciences sectors
In addition to holding an MBA in Health Services Management, Peter has executive education from the Stanford Graduate School of Business, the Harvard Business School and Queen’s University. He has held various board and advisory roles at university-affiliated research institutions, not-for-profit organizations, and for-profit businesses, and currently serves on the advisory board of the clinical research unit of the Montreal Neurological Institute.
Senior Director, Regulatory Affairs
Senior Director of Regulatory Affairs, Sharon Safranyos is responsible for developing, implementing, and advising on global regulatory strategies at BeiGene Canada. Sharon plays a leading role in interacting with Health Canada, anticipating future market dynamics, and ensuring the scientific integrity of sponsored and supported research. With over 20 years of experience as a regulatory affairs professional, she has demonstrated expertise in leadership, negotiations, and product approvals along with extensive knowledge of the highly regulated Canadian healthcare environment.
Sharon started her career in the UK as a Medical Laboratory Scientist in Haematology and Blood Transfusion, with a Fellowship in Transfusion Medicine. She then transitioned into Regulatory Affairs and has spent over 20 years in Regulatory and Quality, both in corporate and as a Senior Consultant.
As BeiGene Canada’s Commercial Lead, Andrea Schwarz is responsible for overseeing sales and marketing, as well as the Patient Support Program (PSP) for the oncology portfolio. A results-oriented leader with over a decade of experience in commercial leadership roles, Andrea has a track record of building high-performing teams to successfully deliver therapies and digital healthcare innovations to patients across Canada.
Prior to joining BeiGene, Andrea served as Director of Sales at TELUS for its Health Care Centres. She has also held Associate Director of Sales positions in immunology. Andrea is a member of the Women Leaders in Pharma Executive Team where she coaches and mentors women as a certified International Coaching Federation (ICF) professional coach.
Nathalie Desrosiers, M.Sc, Ph.D
Senior Director, Value, Access & Policy
As Senior Director, Value Access & Policy, Nathalie Desrosiers leads overall market access strategy in Canada including patient advocacy, reimbursement, health policy and government affairs. A key member of BeiGene Canada’s leadership team, Nathalie partners closely with all functional areas playing a key role in helping to optimize patient access and support business development activities.
With expertise in the areas of health economics, outcomes research, clinical research and health policy, Nathalie has assumed leadership roles related to patient access in the oncology space. She holds a Master of Science Degree in Immunology and Virology from the National Institute of Scientific Research of Montreal and a Doctor of Philosophy Degree from McGill University.
Brad Gillesby, Ph.D
Country Medical Director
With over two decades of experience in the Canadian pharmaceutical industry, specifically in clinical oncology biotechnology, Country Medical Director and scientific lead, Brad Gillesby, oversees the design and implementation of BeiGene Canada’s medical affairs strategy and plays a key role in investigator-initiated research and clinical activities.
A Ph.D in Pharmacology and Toxicology with a specialization in Molecular Biology from Western University, Brad has extensive knowledge of the Canadian regulatory environment. Areas of expertise also include clinical research, health economics, strategic leadership, and corporate medical governance.